Grass Pollen Allergy Clinical Trial
Official title:
A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.
The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
| Completed |
NCT01445002 -
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
|
Phase 2 | |
| Completed |
NCT01830673 -
Regulatory T-cells After Subcutaneous Immunotherapy
|
N/A | |
| Active, not recruiting |
NCT04502966 -
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
|
Phase 2 | |
| Completed |
NCT00263601 -
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT01538979 -
Phase II Study of Grass Pollen Allergy Vaccine BM32
|
Phase 2 | |
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
| Completed |
NCT01308021 -
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
|
Phase 2 | |
| Completed |
NCT00773240 -
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
|
Phase 3 |